ReviewFrontiers in endocrinology2019
Cardioprotection and Thyroid Hormones in the Clinical Setting of Heart Failure.
Review in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Impact of Thyroid Hormone Imbalance on Electrocardiographic Parameters: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Protective role of triiodothyronine in sepsis‑induced cardiomyopathy through phospholamban downregulation.International journal of molecular medicine · 2025Article
- Cardioprotective therapies for ST-elevation myocardial infarction: the emerging role of thyroid hormone: a narrative review.Frontiers in endocrinology · 2025Review
- Predicting major cardiac and cerebrovascular events in acute coronary syndrome patients using the thyroid hormone sensitivity index.Frontiers in endocrinology · 2025Article
- Editorial: Crosstalk between thyroid and heart.Frontiers in endocrinology · 2025Article
- Metabolic Syndrome, Thyroid Dysfunction, and Cardiovascular Risk: The Triptych of Evil.International journal of molecular sciences · 2024Review
- Prognostic implications of thyroid disease in patients with atrial fibrillation.Heart and vessels · 2024Article
- The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions.Current cardiology reviews · 2024Review
- Serum a-1 antitrypsin as a novel biomarker in chronic heart failure.ESC heart failure · 2023Article
- Nrf2-Mediated Antioxidant Defense and Thyroid Hormone Signaling: A Focus on Cardioprotective Effects.Antioxidants (Basel, Switzerland) · 2023Review
- Low Free Triiodothyronine as a More Sensitive Predictor of Survival Than Total Testosterone among Dialysis Men.Nutrients · 2023Article
- Low Free Triiodothyronine Level as a Predictor of Cardiovascular Events and All-Cause Mortality in Patients Undergoing Hemodialysis: The DREAM Cohort.Journal of atherosclerosis and thrombosis · 2021Article
- Vitamin D, Thyroid Hormones and Cardiovascular Risk: Exploring the Components of This Novel Disease Triangle.Frontiers in physiology · 2021Review
- The Pivotal Role of Mitsugumin 53 in Cardiovascular Diseases.Cardiovascular toxicology · 2021Review
- Revisiting the Thyroid-Heart Axis: Unravelling the Interplay of Hormones, Epigenomes and Precision Cardioprotection.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease is the main cause of morbidity and mortality worldwide and is becoming more widespread with population aging. Cardioprotection is a dynamic process characterized by mechanisms related to myocardial damage and activation of protective factors. Targeting these processes could be attractive as a new therapeutic strategy in the evolution of post-ischemic heart failure (HF). In this context, the role of thyroid hormone (TH)-mediated cardioprotection is supported by a number of findings regarding the modulation of neuroendocrine systems, inflammatory and oxidative stress status, pro-survival intracellular pathways, and epigenetic factors, its effects on cardiac angiogenesis, structure, and function and on the preservation of mitochondrial function and morphology, and its beneficial effects on cell growth and redifferentiation. Moreover, the numerous effects of TH on the heart involve genomic mechanisms, which include cardiac differentiation during the perinatal period and non-genomic action, directed toward the maintenance of cardiovascular homeostasis. This evidence suggests that there is an opportunity to treat HF patients with TH. This review is mainly focused on the clinical evidence of the role of the thyroid system in the complex setting of HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.